[{"orgOrder":0,"company":"Alveron Pharma","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"OKL-1111","moa":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Alveron Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"","sponsorNew":"Alveron Pharma \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Alveron Pharma \/ Broadview Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Alveron Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : The financing aims to advance the development of its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage.

                          Brand Name : OKL-1111

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 06, 2024

                          Lead Product(s) : OKL-1111

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Sponsor : Broadview Ventures

                          Deal Size : $5.2 million

                          Deal Type : Financing

                          blank